Top-Rated Stocks NASDAQ:ASND Ascendis Pharma A/S - ASND Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. $104.90 -0.59 (-0.56%) (As of 03/24/2023 04:28 PM ET) Add Compare Share Share Today's Range$103.33▼$105.7250-Day Range$105.49▼$124.0852-Week Range$61.58▼$134.52Volume154,804 shsAverage Volume259,876 shsMarket Capitalization$6.00 billionP/E RatioN/ADividend YieldN/APrice Target$160.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Ascendis Pharma A/S MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside53.0% Upside$160.50 Price TargetShort InterestBearish5.74% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($11.03) to ($7.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.71 out of 5 starsMedical Sector805th out of 989 stocksPharmaceutical Preparations Industry390th out of 480 stocks 3.5 Analyst's Opinion Consensus RatingAscendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $160.50, Ascendis Pharma A/S has a forecasted upside of 53.0% from its current price of $104.90.Amount of Analyst CoverageAscendis Pharma A/S has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.74% of the outstanding shares of Ascendis Pharma A/S have been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Ascendis Pharma A/S has recently decreased by 1.20%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASND. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 4 news articles for Ascendis Pharma A/S this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for ASND on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($11.03) to ($7.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is -9.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is -9.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAscendis Pharma A/S has a P/B Ratio of 21.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ascendis Pharma A/S (NASDAQ:ASND) StockAscendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.Read More Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ASND Stock News HeadlinesMarch 24, 2023 | markets.businessinsider.comAscendis Pharma (ASND) Receives a Buy from Morgan StanleyMarch 22, 2023 | markets.businessinsider.comMoonLake Immunotherapeutics (MLTX) Receives a New Rating from WedbushMarch 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 22, 2023 | markets.businessinsider.comMorgan Stanley Sticks to Its Buy Rating for Ascendis Pharma (ASND)March 17, 2023 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Now Covered by StockNews.comMarch 14, 2023 | seekingalpha.comASND Ascendis Pharma A/SMarch 10, 2023 | finance.yahoo.comAscendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceFebruary 20, 2023 | finance.yahoo.comAscendis Pharma A/S (NASDAQ:ASND) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.February 18, 2023 | finance.yahoo.comAscendis Pharma Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsFebruary 17, 2023 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Ascendis Pharma (ASND)February 17, 2023 | markets.businessinsider.comMorgan Stanley Reaffirms Their Buy Rating on Ascendis Pharma (ASND)February 16, 2023 | finance.yahoo.comAscendis Pharma Reports Full Year 2022 ResultsFebruary 7, 2023 | finance.yahoo.comAscendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16February 3, 2023 | markets.businessinsider.comAnalyst Expectations for Ascendis Pharma's FutureJanuary 31, 2023 | finance.yahoo.comWhat Makes Ascendis Pharma A/S (ASND) an Attractive Investment Choice?January 19, 2023 | seekingalpha.comAscendis Pharma: Group's Best Nearby Capital Gain Price-Position StockJanuary 8, 2023 | finance.yahoo.comAscendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2023 | finance.yahoo.comAscendis Pharma's (NASDAQ:ASND) growing losses don't faze investors as the stock climbs 3.8% this past weekJanuary 4, 2023 | finance.yahoo.comOnline Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma’s TransCon™ PTH for Eligible U.S. Adult Patients with HypoparathyroidismJanuary 3, 2023 | nz.finance.yahoo.comAscendis Pharma to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2023 | finance.yahoo.comAscendis Pharma to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 27, 2022 | finance.yahoo.comHere’s the Reason for the Healthy Performance of Ascendis Pharma A/S (ASND)December 5, 2022 | finance.yahoo.comAscendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with HypoparathyroidismNovember 29, 2022 | markets.businessinsider.comWhat 9 Analyst Ratings Have To Say About Ascendis PharmaNovember 22, 2022 | finance.yahoo.comAscendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx ConferenceNovember 14, 2022 | seekingalpha.comAscendis falls on Phase 2 data for achondroplasia candidateSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ASND Company Calendar Last Earnings2/16/2023Today3/24/2023Next Earnings (Estimated)5/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASND CUSIPN/A CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees639Year FoundedN/APrice Target and Rating Average Stock Price Forecast$160.50 High Stock Price Forecast$182.00 Low Stock Price Forecast$130.00 Forecasted Upside/Downside+54.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($10.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-614,450,000.00 Net Margins-1,149.60% Pretax Margin-1,129.12% Return on Equity-114.11% Return on Assets-45.20% Debt Debt-to-Equity Ratio1.83 Current Ratio5.39 Quick Ratio4.63 Sales & Book Value Annual Sales$53.93 million Price / Sales110.09 Cash FlowN/A Price / Cash FlowN/A Book Value$4.87 per share Price / Book21.33Miscellaneous Outstanding Shares57,150,000Free Float34,291,000Market Cap$5.94 billion OptionableOptionable Beta0.55 Key ExecutivesJan Møller MikkelsenPresident, CEO & Executive DirectorScott Thomas SmithChief Financial Officer & Senior Vice PresidentKennett SprogøeSenior Vice President, Head-Innovation & ResearchBirgitte VolckSVP, Head-Clinical Development & Medical AffairsStina SingelSenior Vice President & Head-Clinical DevelopmentKey CompetitorsKaruna TherapeuticsNASDAQ:KRTXOrganon & Co.NYSE:OGNRoivant SciencesNASDAQ:ROIVLegend BiotechNASDAQ:LEGNApellis PharmaceuticalsNASDAQ:APLSView All CompetitorsInstitutional OwnershipVoya Investment Management LLCBought 9,805 shares on 2/28/2023Ownership: 0.044%Alliancebernstein L.P.Sold 149,930 shares on 2/16/2023Ownership: 0.859%State of Wisconsin Investment BoardSold 541 shares on 2/15/2023Ownership: 0.027%Mackenzie Financial CorpBought 733 shares on 2/15/2023Ownership: 0.011%Centiva Capital LPBought 2,500 shares on 2/15/2023Ownership: 0.000%View All Institutional Transactions ASND Stock - Frequently Asked Questions Should I buy or sell Ascendis Pharma A/S stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ASND shares. View ASND analyst ratings or view top-rated stocks. What is Ascendis Pharma A/S's stock price forecast for 2023? 10 Wall Street analysts have issued 1-year price objectives for Ascendis Pharma A/S's shares. Their ASND share price forecasts range from $130.00 to $182.00. On average, they anticipate the company's share price to reach $160.50 in the next year. This suggests a possible upside of 54.9% from the stock's current price. View analysts price targets for ASND or view top-rated stocks among Wall Street analysts. How have ASND shares performed in 2023? Ascendis Pharma A/S's stock was trading at $122.13 at the start of the year. Since then, ASND shares have decreased by 15.2% and is now trading at $103.60. View the best growth stocks for 2023 here. When is Ascendis Pharma A/S's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our ASND earnings forecast. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) posted its earnings results on Thursday, February, 16th. The biotechnology company reported ($3.78) earnings per share for the quarter, missing the consensus estimate of ($2.50) by $1.28. The biotechnology company earned $23.38 million during the quarter, compared to analysts' expectations of $20.31 million. Ascendis Pharma A/S had a negative net margin of 1,149.60% and a negative trailing twelve-month return on equity of 114.11%. What ETFs hold Ascendis Pharma A/S's stock? ETFs with the largest weight of Ascendis Pharma A/S (NASDAQ:ASND) stock in their portfolio include Harbor Health Care ETF (MEDI), Putnam BioRevolution ETF (SYNB), Virtus LifeSci Biotech Products ETF (BBP), Global X Guru Index ETF (GURU), American CenturyFocused Dynamic Growth ETF (FDG), Harbor Disruptive Innovation ETF (INNO), First Trust NASDAQ BuyWrite Income ETF (FTQI) and Putnam Sustainable Future ETF (PFUT). What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA). When did Ascendis Pharma A/S IPO? (ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager. What is Ascendis Pharma A/S's stock symbol? Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND." Who are Ascendis Pharma A/S's major shareholders? Ascendis Pharma A/S's stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (12.20%), Artisan Partners Limited Partnership (12.14%), Price T Rowe Associates Inc. MD (6.51%), Avoro Capital Advisors LLC (5.44%), T. Rowe Price Investment Management Inc. (4.96%) and Franklin Resources Inc. (2.42%). How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ascendis Pharma A/S's stock price today? One share of ASND stock can currently be purchased for approximately $103.60. How much money does Ascendis Pharma A/S make? Ascendis Pharma A/S (NASDAQ:ASND) has a market capitalization of $5.92 billion and generates $53.93 million in revenue each year. The biotechnology company earns $-614,450,000.00 in net income (profit) each year or ($10.85) on an earnings per share basis. How many employees does Ascendis Pharma A/S have? The company employs 639 workers across the globe. How can I contact Ascendis Pharma A/S? Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The official website for the company is www.ascendispharma.com. The biotechnology company can be reached via phone at (457) 022-2244, via email at ir@ascendispharma.com, or via fax at 45-3694-4010. This page (NASDAQ:ASND) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.